Phase II. Evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000609:Aminoacridines / Q000009:adverse effects / Q000627:therapeutic use*; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine